Medicine
Review Cycle Records
Expert Review of Pharmacoeconomics & Outcomes Research
Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Cost-effectiveness of umeclidinium/vilanterol versus aclidinium monotherapy for symptomatic COPD in Colombia: a lifetime Markov model
Jefferson Antonio BuendíaShow moreShow less
1. Universidad de AntioquiaShow moreShow less
Affordability and relative economic burden of multiple sclerosis biologics in South America: a cross-country analysis of prices, purchasing power and regulatory access
Priscila Madeira da Silva Oliveira; Cid Manso de Mello Vianna; Alfonso Jesus Gil Lopez; Gabriela Bittencourt Gonzalez MoseguiShow moreShow less
1. Fluminense Federal University; 2. Rio de Janeiro State University; 3. University of La RiojaShow moreShow less
Health-related quality of life in adult patients with moyamoya disease in Japan: a single-center study
Honoka Tamori; Toshiya Osanai; Haruto Uchino; Katsuhiko Ogasawara; Miki FujimuraShow moreShow less
1. Hokkaido University; 2. National Institute of Public HealthShow moreShow less
Cost-effectiveness of neoadjuvant/adjuvant pembrolizumab versus standard of care for locally advanced head and Neck squamous cell carcinoma in China and the United States
Ruixuan Liu; Zhen Wang; Xueli Yang; Yong Xiao; Zeqin Liu; Qing YangShow moreShow less
1. Chengdu University of Traditional Chinese Medicine; 2. The Affiliated Hospital of Southwest Medical University; 3. University of Electronic Science and Technology of ChinaShow moreShow less
Nivolumab dose stewardship in routine Oncology practice: a real-world health-economic simulation
Arif Hakan Önder; Mehmet Mutlu Çatlı; Olgun KeskinShow moreShow less
1. Antalya Education and Research HospitalShow moreShow less
Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung Cancer in China
Yanhui Li; Yafei ShiShow moreShow less
1. Chinese Academy of Medical Sciences; 2. Chinese Academy of Medical Sciences and Peking Union Medical CollegeShow moreShow less
FAQ
How long does Expert Review of Pharmacoeconomics & Outcomes Research take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for Expert Review of Pharmacoeconomics & Outcomes Research. The fastest paper went from submission to acceptance in 20 days (Health-related quality of life in adult patients with moyamoya disease in Japan: a single-center study, received 2026-09-24, accepted 2026-10-14); the slowest took 168 days. The average is 102.1 days and the median is 99 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.